Zhu Zhipeng, Zhou Hongmei, Ni Yunjian, Wu Cheng, Zhang Caijun, Ling Xiaoyan
Department of Anesthesiology, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Outpatient-Nursing Department, the Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Drug Des Devel Ther. 2018 Mar 12;12:521-531. doi: 10.2147/DDDT.S153834. eCollection 2018.
Cardiac surgery patients always present with atrial fibrillation (AF) after admission to the intensive care unit, leading to high mortality and lengthy hospitalization. Dexmedetomidine (DEX) is a popular medication used for sedation in the intensive care unit; however, whether it can reduce AF needs to be analyzed.
Three primary databases, Medline, Embase (Ovid SP) and the Cochrane Central Register of Controlled Trials (CENTRAL), were searched. All English language and randomized control designed clinical publications comparing DEX to control medicines for sedation after elective cardiac surgery were included. Two independent colleagues conducted the data extraction and quality assessments. The subgroup analysis was performed according to the medicine used, age, AF history, and whether previous beta-blocker premedication and cardiopulmonary bypass (CPB) were applied. The overall incidence of AF was analyzed.
A total of 1,295 patients in nine studies met the selection criteria among 2,587 studies screened from the database. After quantitative synthesis, our results revealed that the DEX group was not associated with a decreased incidence of AF compared with the placebo (risk ratio [RR] 0.76, 95% CI 0.37, 1.55, =0.44) and morphine groups (RR 0.86, 95% CI 0.56, 1.31, =0.48). Subgroup analysis also indicated that the DEX vs propofol comparison exhibited no difference: 1) for patients of age >60 years (=0.69) or ≤60 years (=0.69); 2) under CPB surgery (=0.45) or without CPB surgery (=0.88); 3) with beta-blocker premedication (=0.32) or without beta-blocker premedication (=0.90); and 4) with AF history (RR 1.07, 95% CI 0.85, 1.36, =0.57) or without AF history (=0.30).
This meta-analysis revealed that DEX could not reduce the incidence of AF compared to control medicines following cardiac surgery. DEX may have an increased influence on AF occurrence if patients had a history of AF. However, cautious interpretation should be made due to high clinical heterogeneity.
心脏手术患者入住重症监护病房后常出现心房颤动(AF),导致高死亡率和住院时间延长。右美托咪定(DEX)是重症监护病房常用的镇静药物;然而,其是否能降低房颤发生率尚需分析。
检索了三个主要数据库,即Medline、Embase(Ovid SP)和Cochrane对照试验中央注册库(CENTRAL)。纳入所有比较DEX与对照药物用于择期心脏手术后镇静的英文且设计为随机对照的临床出版物。两名独立的研究人员进行数据提取和质量评估。根据所用药物、年龄、房颤病史以及是否应用过β受体阻滞剂预处理和体外循环(CPB)进行亚组分析。分析房颤的总体发生率。
在从数据库筛选的2587项研究中,共有9项研究中的1295例患者符合入选标准。定量综合分析后,我们的结果显示,与安慰剂组(风险比[RR]0.76,95%可信区间0.37,1.55,P = 0.44)和吗啡组(RR 0.86,95%可信区间0.56,1.31,P = 0.,48)相比,DEX组房颤发生率并未降低。亚组分析还表明,DEX与丙泊酚比较无差异:1)年龄>60岁(P = 0.69)或≤60岁(P = 0.69)的患者;2)接受CPB手术(P = 0.45)或未接受CPB手术(P = 0.88)的患者;3)应用β受体阻滞剂预处理(P = 0.32)或未应用β受体阻滞剂预处理(P = 0.90)的患者;4)有房颤病史(RR 1.0,可信区间0.85,1.36,P = 0.57)或无房颤病史(P = 0.30)的患者。
这项荟萃分析表明,心脏手术后,与对照药物相比,DEX不能降低房颤发生率。如果患者有房颤病史,DEX可能对房颤发生有更大影响。然而,由于临床异质性高,应谨慎解读。